Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Lars D. Köthe"'
Autor:
Michael A. Nauck, Joachim Kind, Jens J. Holst, James E. Foley, Lars D. Köthe, Yan-Ling He, Lise Kjems, Carolyn F. Deacon, Matthias Broschag
Publikováno v:
Diabetes. 65(8)
We quantified the contribution of GLP-1 as a mediator of the therapeutic effects of dipeptidyl peptidase 4 (DPP-4) inhibition (vildagliptin) by using the GLP-1 receptor antagonist exendin [9-39] in patients with type 2 diabetes and in healthy subject
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62322ce7657474c918ca4a3c2e4568f4
https://pubmed.ncbi.nlm.nih.gov/27456619
https://pubmed.ncbi.nlm.nih.gov/27456619
Autor:
Nikolaos Mentis, Michael A. Nauck, Juris J. Meier, Carolyn F. Deacon, Lars D. Köthe, Jens J. Holst, Michael J. Theodorakis, Irfan Vardarli
Publikováno v:
Diabetes
OBJECTIVE The incretin glucagon-like peptide 1 (GLP-1) exerts insulinotropic activity in type 2 diabetic patients, whereas glucose-dependent insulinotropic polypeptide (GIP) no longer does. We studied whether GIP can alter the insulinotropic or gluca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1db355038c14f99040a789274a1baac9
https://doi.org/10.2337/db10-1332
https://doi.org/10.2337/db10-1332
Autor:
Irfan Vardarli, Anja Schweizer, Michael A. Nauck, Lars D. Köthe, James E. Foley, Jens J. Holst, Carolyn F. Deacon
Publikováno v:
The Journal of clinical endocrinology and metabolism. 96(4)
Background and Aims: Dipeptidyl peptidase-4 (DPP-4) inhibitors block the degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. The aim of the present study was to quantitatively assess the incretin effect after trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d568444d438bc022e30a7e8c53717b8f
https://pubmed.ncbi.nlm.nih.gov/21474688
https://pubmed.ncbi.nlm.nih.gov/21474688